Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-01-09
DOI
10.1038/srep39604
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice
- (2016) Sarah A. Marshall et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice
- (2016) Vedat Tiyerili et al. ATHEROSCLEROSIS
- Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin)
- (2016) C H Leo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na+ channels
- (2016) Brian L. Henry et al. HEART RHYTHM
- Endothelium dependent hyperpolarization-type relaxation compensates for attenuated nitric oxide-mediated responses in subcutaneous arteries of diabetic patients
- (2016) Siti Safiah Mokhtar et al. NITRIC OXIDE-BIOLOGY AND CHEMISTRY
- Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta
- (2016) Hooi Hooi Ng et al. PHARMACOLOGICAL RESEARCH
- Antifibrotic Actions of Serelaxin – New Roles for an Old Player
- (2016) Chrishan S. Samuel et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Serelaxin: A Novel Therapeutic for Vascular Diseases
- (2016) Chen Huei Leo et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice
- (2015) Hooi H. Ng et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Chronic Administration of the Nitroxyl Donor 1-Nitrosocyclo Hexyl Acetate Limits Left Ventricular Diastolic Dysfunction in a Mouse Model of Diabetes Mellitus In Vivo
- (2015) N. Cao et al. Circulation-Heart Failure
- Relaxin-2 Does Not Ameliorate Nephropathy in an Experimental Model of Type-1 Diabetes
- (2015) Thomas Bernd Dschietzig et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Effects of recombinant human relaxin upon proliferation of cardiac fibroblast and synthesis of collagen under high glucose condition
- (2014) P. Wang et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis
- (2014) Bryna S. Man Chow et al. KIDNEY INTERNATIONAL
- Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways
- (2014) Karina Huynh et al. PHARMACOLOGY & THERAPEUTICS
- Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation
- (2014) Chen Huei Leo et al. Journal of the American Heart Association
- Role of protein kinase C β2 in relaxin-mediated inhibition of cardiac fibrosis
- (2014) W. Su et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts
- (2013) Ashish Parikh et al. CIRCULATION RESEARCH
- Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice
- (2013) Alessandra Bitto et al. CLINICAL SCIENCE
- Relaxin Treatment Reverses Insulin Resistance in Mice Fed a High-Fat Diet
- (2013) Jeffrey S. Bonner et al. DIABETES
- Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment
- (2013) Maria Jelinic et al. FASEB JOURNAL
- Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice
- (2013) Karina Huynh et al. FREE RADICAL BIOLOGY AND MEDICINE
- Relaxin Prevents Cardiac Fibroblast-Myofibroblast Transition via Notch-1-Mediated Inhibition of TGF-β/Smad3 Signaling
- (2013) Chiara Sassoli et al. PLoS One
- Relaxin improves TNF-α-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling
- (2012) Thomas Dschietzig et al. CARDIOVASCULAR RESEARCH
- Enhanced phosphoinositide 3-kinase(p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes
- (2012) R. H. Ritchie et al. DIABETOLOGIA
- Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice
- (2011) Wing Tak Wong et al. Cell Metabolism
- Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ
- (2011) Siu-Lung Chan et al. FASEB JOURNAL
- Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment
- (2011) Inês Falcão-Pires et al. HEART FAILURE REVIEWS
- Relaxin Ameliorates Hypertension and Increases Nitric Oxide Metabolite Excretion in Angiotensin II But Not N ω -Nitro- l -Arginine Methyl Ester Hypertensive Rats
- (2011) Jennifer M. Sasser et al. HYPERTENSION
- Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes
- (2010) CH Leo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiac-Specific IGF-1 Receptor Transgenic Expression Protects Against Cardiac Fibrosis and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy
- (2010) K. Huynh et al. DIABETES
- Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials
- (2009) Jay S. Skyler et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relaxin Ameliorates Fibrosis in Experimental Diabetic Cardiomyopathy
- (2008) Chrishan S. Samuel et al. ENDOCRINOLOGY
- Endothelial Dysfunction in Mice with Streptozotocin-induced Type 1 Diabetes Is Opposed by Compensatory Overexpression of Cyclooxygenase-2 in the Vasculature
- (2008) Carmela Nacci et al. ENDOCRINOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started